5-MeO-DMT: Benefits, Risks, and Getting Started

5-MeO-DMT:
Benefits, Risks,
and Getting Started
Recording filmed Sunday, May 31, 2026
Free live DoubleBlind workshop

What to know about the God Molecule

Since Bryan Johnson livestreamed his experience on 5-MeO-DMT, the “God Molecule” has been getting a lot of attention. 5-MeO, sometimes referred to as “toad medicine,” is widely considered one of the strongest psychedelics known. It is often associated with mystical experiences and ego dissolution, and it has shown promise for treatment-resistant depression, anxiety, and PTSD.

At the same time, 5-MeO vape pens are appearing in underground markets at both small and large doses. Is this a psychedelic you should try? How does it differ from shrooms, LSD, and other better-known psychedelics? What should you know before diving in? Join Joel Brierre and Victoria Wueschner for a grounded conversation on benefits, risks, safety, ethics, and getting started.

About Our Guests

Who is Victoria Wueschner?

Victoria Wueschner is the co-founder and president of F.I.V.E. (5-MeO-DMT Information and Vital Education), a company offering trainings, protocols, research, and resources for the 5-MeO-DMT space. Her work centers ethics, integrity, and safety, and she has collaborated on research projects with University College London and Imperial College London. Victoria is also a head retreat leader at Tandava Retreats in Mexico and specializes in working with women survivors of sexual trauma.

Who is Joel Brierre?

Joel Brierre is the founder of KVI, an ecosystem exploring the therapeutic and scientific potential of 5-MeO-DMT. Joel and his team collaborate with universities and researchers to better understand the neurological outcomes of this molecule, including the first official EEG study of the 5-MeO peak experience. KVI is the parent company to Tandava, FIVE Education, and Five Discovery, spanning integrative retreats, education, training, and drug discovery inspired by 5-MeO-DMT.

Mary Carreon

Moderator

Mary Carreon is a journalist whose work explores the intersections of culture, drug policy, pharma, and the environment. As the Editor-in-Chief at DoubleBlind, she empowers writers to craft stories that spark meaningful dialogue and encourage readers to think and engage with diverse issues.